Sotolasib (Lumakras)

Ingredients: Sotorasib
Dosage Form: Oral tablets
Innovator’s Brand Name: Lumakras
Generic Brand Name: Sotakras
Generic Manufacturer: Ziska Pharma

Indications:
Sotorasib is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer who have received at least one prior systemic therapy.

Dosage and Administration:
The recommended dose is 960 mg orally once daily (as a single dose or divided into two doses), taken at the same time each day, with or without food. If a dose is missed by more than 6 hours, skip that dose and resume the regular schedule—do not double the next dose. If vomiting occurs after dosing, do not replace the dose.

Adverse Reactions:
Common serious adverse reactions include hepatotoxicity and interstitial lung disease, manifested by abnormal liver function tests (elevated transaminases and bilirubin), cough, dyspnea, and fever. Patients experiencing these should seek medical attention immediately and have their treatment adjusted.

Storage:
Store in a cool, dry place at or below 25 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link